Syndax Pharmaceuticals Inc. Common Stock (SNDX)

About SNDX

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also dev…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

298

Website

syndax.com/

Fundamentals

1-day range

$19.47$20.05

Market cap

$1.76B

P/E (trailing)

—

P/E (forward)

-23.95

EPS (trailing)

$-2.52

Dividend yield

—

Beta

0.42

Avg. volume

1.81M

Forecasts

11 analyst ratings

Syndax Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SNDX

  Syndax Pharmaceuticals Inc. Common Stock

  $19.55

  ▼ 3.05%
  Market cap $1.76BP/E —
  $12.99$25.59
• SRPT

  Sarepta Therapeutics Inc. Common Stock (DE)

  $20.85

  ▼ 3.43%
  Market cap $1.77BP/E —
• GENB

  Generate Biomedicines Inc. Common Stock

  $15.33

  ▼ 2.79%
  Market cap $1.78BP/E —
  $11$22.67
• LKFT

  Lakefront Biotherapeutics American Depositary Shares

  $28.86

  ▼ 1.97%
  Market cap $1.72BP/E 3.29
  $22.32$27.12
• BCAX

  Bicara Therapeutics Inc. Common Stock

  $23.42

  ▼ 5.70%
  Market cap $1.81BP/E —
  $10.3$30.99
• CMPS

  COMPASS Pathways Plc American Depository Shares

  $13.71

  ▼ 6.35%
  Market cap $1.83BP/E —
• NBTX

  Nanobiotix S.A. American Depositary Shares

  $41.28

  ▼ 8.59%
  Market cap $1.83BP/E —
  $7.02$47.66

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
  Yahoo · 8/22/2026
• UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33
  Benzinga · 8/21/2026
• Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?
  Yahoo · 8/12/2026
• Syndax (SNDX) Q2 2026 Earnings Call Transcript
  Yahoo · 8/12/2026
• JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40
  Benzinga · 8/11/2026
• How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors
  Yahoo · 8/7/2026
• Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  Yahoo · 8/5/2026
• Syndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/5/2026

• Michael A. Metzger · July 8, 2026 · Option Exercise

  32.4K @ $6.38
• Michael A. Metzger · July 8, 2026 · Sale

  32.4K @ $24.24
• Nicholas A.J. Botwood · June 12, 2026 · Option Exercise

  31.2K @ $13.82
• Nicholas A.J. Botwood · June 12, 2026 · Sale

  31.2K @ $18.14
• Nicholas A.J. Botwood · June 11, 2026 · Option Exercise

  22.5K @ $13.82
• Nicholas A.J. Botwood · June 11, 2026 · Sale

  34.3K @ $18
• Keith A. Goldan · June 1, 2026 · Sale

  1.2K @ $18.99
• Michael A. Metzger · June 1, 2026 · Sale

  6.8K @ $18.99

Institutional Ownership

March 31, 2026

Total shares held

97.23M

Total value held

$2.24B

Institutional holders

237